Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics Inc (NQ: ARQT )

10.80 -0.06 (-0.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 958,884
Open 10.98
Bid (Size) 10.79 (5)
Ask (Size) 10.80 (349)
Prev. Close 10.86
Today's Range 10.74 - 11.16
52wk Range 10.65 - 27.40
Shares Outstanding 50,241,789
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting
From Arcutis Biotherapeutics, Inc.
Via Globe NewsWire
Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting
From Arcutis Biotherapeutics, Inc.
Via Globe NewsWire

Performance

YTD
-26.88%
-26.88%
1 Month
-33.25%
-33.25%
3 Month
-24.21%
-24.21%
6 Month
-41.50%
-41.50%
1 Year
-38.57%
-38.57%

More News

Read More
Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via Globe NewsWire
Arcutis Biotherapeutics's Earnings Outlook
Via Benzinga
Arcutis Shares Gain On Positive Phase 3 Data On Roflumilast Foam In Scalp, Body Psoriasis
Via Benzinga
Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
From Arcutis Biotherapeutics, Inc.
Via Globe NewsWire
Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference
From Arcutis Biotherapeutics, Inc.
Via Globe NewsWire
Arcutis' Flagship Psoriasis Treatment Shows Sustained Efficacy, Clearance For Median Of 10 Months
Via Benzinga
Atopic Dermatitis Player Arcutis Scoops Up DucentisBioTherapeutics
Via Benzinga
Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis
From Arcutis Biotherapeutics, Inc.
Via Globe NewsWire
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age
From Arcutis Biotherapeutics, Inc.
Via Globe NewsWire
Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older
From Arcutis Biotherapeutics, Inc.
Via Globe NewsWire
Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255
From Arcutis Biotherapeutics, Inc.
Via Globe NewsWire
Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology
From Arcutis Biotherapeutics, Inc.
Via Globe NewsWire
Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report
From Arcutis Biotherapeutics, Inc.
Via Globe NewsWire
Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States
From Arcutis Biotherapeutics, Inc.
Via Globe NewsWire
CORRECTION -- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older
From Arcutis Biotherapeutics, Inc.
Via Globe NewsWire
Arcutis Biotherapeutics Stock Surges After Successful Atopic Dermatitis Trial
Via Benzinga
Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older
From Arcutis Biotherapeutics, Inc.
Via Globe NewsWire
Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing
Via Investor's Business Daily
Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via Globe NewsWire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis
From Arcutis Biotherapeutics, Inc.
Via Globe NewsWire
What 4 Analyst Ratings Have To Say About Arcutis Biotherapeutics
Via Benzinga
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.